Novel Drug Delivery System Market Size, Share, Opportunities, And Trends By Route of Administration (Oral Drug Delivery Systems, Injectable Drug Delivery Systems, Pulmonary Drug Delivery Systems, Transdermal Drug Delivery Systems, Other Routes of Administration), By Mode of NDDS (Targeted Drug Delivery Systems, Controlled Drug Delivery Systems, Modulated Drug Delivery Systems), By End User (Hospital, Research Centers, Specialty Clinics, Others), And By Geography - Forecasts From 2024 To 2029

The novel drug delivery system market is experiencing significant growth, propelled by the escalating need for controlled and effective drug administration in the face of rising chronic diseases such as diabetes, cardiovascular ailments, renal diseases, asthma, and cancer. The increasing awareness of these conditions is driving demand for advanced therapeutics, spurring companies to invest in innovative drug delivery systems. This market expansion is further fueled by technological advancements, substantial investments from private and government entities, and strategic initiatives such as new product launches and collaborations. The rising global burden of chronic diseases underscores the demand for innovative drug delivery solutions, making the novel drug delivery system market a dynamic and promising sector for the future.

Market Drivers

• Rising demand for drug delivery systems

The global novel drug delivery systems market is experiencing substantial growth, primarily propelled by the escalating demand for controlled drug delivery systems, a response to the rising prevalence of chronic diseases like diabetes, cardiovascular issues, renal disease, asthma, and cancer. The awareness surrounding these conditions is increasing, leading to a heightened need for advanced and effective therapeutics. This growing demand catalyzes companies to invest in the development of novel drug delivery systems, thereby stimulating market expansion. A research study published in the Journal of the Formosan Medical Association in October 2021 highlighted the prevalence of carotid plaque and diabetes mellitus (DM) in individuals aged 40 to 74, revealing significant rates of 34.4% and 10.7%, respectively. Moreover, age-specific prevalence rates of DM and carotid plaque displayed a linear correlation in both genders within the studied population. This data underscores the substantial global burden of chronic diseases. Similarly, data from the Global Cancer Observatory updated in March 2021 projected a surge in the global cancer burden from 19.3 million to 28.9 million by 2040. Consequently, the escalating burden of chronic diseases is anticipated to drive investments and advancements in the development of novel drug delivery systems, fostering market growth throughout the forecast period.

• Technological Advancements

Technological advancements in drug delivery systems, coupled with increased investments from both private and government entities, as well as key companies engaging in new product launches, collaborations, and mergers and acquisitions, are anticipated to provide a significant boost to the novel drug delivery systems market growth. An illustrative example is the introduction of a novel Dual Chamber Bags (DCB) drug delivery system by Gufic Biosciences Ltd. in June 2022. These innovative 2-chamber IV bags, crafted from polypropylene (DEHP free) with peelable aluminum foil, enable the storage of unstable drugs requiring reconstitution just before administration to the patient. Consequently, these factors are expected to contribute to the novel drug delivery systems market expansion over the forecast period.

North America is anticipated to hold a significant share of the market

North America is poised to be the dominant force in the novel drug delivery systems market, driven by a surge in research endeavours focused on new therapies, augmented budgets for innovative drug discovery, and heightened awareness regarding novel drug delivery systems. The region grapples with an increasing prevalence of chronic diseases and conditions, with estimates from the Global Cancer Observatory predicting 2.3 million new cancer cases by 2045 in the United States alone. Notable cancers in the region include breast cancer, lung cancer, prostate cancer, colorectal cancer, bladder cancer, and skin cancer. The escalating burden of cancer and other chronic diseases stemming from environmental and lifestyle changes is expected to propel the demand for advanced drug delivery options for the secure administration of biologics, thereby fostering market growth in the foreseeable future.

Moreover, companies in North America are actively engaged in innovating novel drug delivery systems, expanding market presence, and launching new products, contributing to the region's market growth. For instance, in May 2022, Jabil Healthcare introduced the Qfinity autoinjector platform, offering a simple, reusable, and modular solution for subcutaneous drug self-administration at a lower cost than existing alternatives, aligning with the growing emphasis on sustainable drug delivery in the pharmaceutical industry. Additionally, in October 2022, NuGen Medical Devices Inc., a key player in needle-free drug delivery, officially introduced its InsuJet devices in Canada. These strategic product launches are expected to further drive market growth in the region. Consequently, the increasing patient population with chronic disorders and the continuous development and release of technologically advanced drug delivery systems are anticipated to propel the novel drug delivery systems market in North America throughout the forecast period.

Market Developments

• In June 2022, Esteve Pharmaceuticals GmbH introduced INBRIJA 33 mg (levodopa inhalation powder, hard capsules) in Germany. The EU indication for INBRIJA is the intermittent treatment of episodic motor fluctuations in adult patients diagnosed with Parkinson's disease who are undergoing levodopa/dopa-decarboxylase inhibitor therapy.
• In June 2022, EVERSANA collaborated with Accord BioPharma to facilitate the recent introduction of CAMCEVI (leuprolide) 42mg injection emulsion for the treatment of advanced prostate cancer in adults.

Market Segmentation

• By Route of Administration
  • Oral Drug Delivery Systems
  • Injectable Drug Delivery Systems
  • Pulmonary Drug Delivery Systems
  • Transdermal Drug Delivery Systems
  • Other Routes of Administration
• By Mode of NDDS
  • Targeted Drug Delivery Systems
  • Controlled Drug Delivery Systems
  • Modulated Drug Delivery Systems
• By End User
  • Hospital
  • Research Centers
  • Specialty Clinics
  • Others
• By Geography
  • North America
    • USA
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Taiwan
    • Thailand
    • Indonesia
    • Others

1. INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline

1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY  

2.1. Research Design

2.2. Research Processes

3. EXECUTIVE SUMMARY

3.1. Key Findings

3.2. Analyst View

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Forces Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

4.5. Analyst View

5. NOVEL DRUG DELIVERY SYSTEMS MARKET BY ROUTE OF ADMINISTRATION 

5.1. Introduction

5.2. Oral Drug Delivery Systems

5.2.1. Market Trends and Opportunities

5.2.2. Growth Prospects

5.3. Injectable Drug Delivery Systems

5.3.1. Market Trends and Opportunities

5.3.2. Growth Prospects

5.4. Pulmonary Drug Delivery Systems

5.4.1. Market Trends and Opportunities

5.4.2. Growth Prospects

5.5. Transdermal Drug Delivery Systems

5.5.1. Market Trends and Opportunities

5.5.2. Growth Prospects

5.6. Other Routes of Administration 

5.6.1. Market Trends and Opportunities

5.6.2. Growth Prospects

6. NOVEL DRUG DELIVERY SYSTEMS MARKET BY MODE OF NDDS 

6.1. Introduction

6.2. Targeted Drug Delivery Systems

6.2.1. Market Trends and Opportunities

6.2.2. Growth Prospects

6.3. Controlled Drug Delivery Systems

6.3.1. Market Trends and Opportunities

6.3.2. Growth Prospects

6.4. Modulated Drug Delivery Systems 

6.4.1. Market Trends and Opportunities

6.4.2. Growth Prospects

7. NOVEL DRUG DELIVERY SYSTEMS MARKET BY END-USER

7.1. Introduction

7.2. Hospital

7.2.1. Market Trends and Opportunities

7.2.2. Growth Prospects

7.3. Research Centers

7.3.1. Market Trends and Opportunities

7.3.2. Growth Prospects

7.4. Specialty Clinics

7.4.1. Market Trends and Opportunities

7.4.2. Growth Prospects

7.5. Others

7.5.1. Market Trends and Opportunities

7.5.2. Growth Prospects

8. NOVEL DRUG DELIVERY SYSTEMS MARKET BY GEOGRAPHY

8.1. Introduction

8.2. North America

8.2.1. By Route of Administration 

8.2.2. By Mode of NDDS

8.2.3. By End User

8.2.4. By Country

8.2.4.1. United States

8.2.4.1.1. Market Trends and Opportunities

8.2.4.1.2. Growth Prospects

8.2.4.2. Canada

8.2.4.2.1. Market Trends and Opportunities

8.2.4.2.2. Growth Prospects

8.2.4.3. Mexico

8.2.4.3.1. Market Trends and Opportunities

8.2.4.3.2. Growth Prospects

8.3. South America

8.3.1. By Route of Administration 

8.3.2. By Mode of NDDS

8.3.3. By End User

8.3.4. By Country 

8.3.4.1. Brazil

8.3.4.1.1. Market Trends and Opportunities

8.3.4.1.2. Growth Prospects

8.3.4.2. Argentina

8.3.4.2.1. Market Trends and Opportunities

8.3.4.2.2. Growth Prospects

8.3.4.3. Others

8.3.4.3.1. Market Trends and Opportunities

8.3.4.3.2. Growth Prospects

8.4. Europe

8.4.1. By Route of Administration 

8.4.2. By Mode of NDDS

8.4.3. By End User

8.4.4. By Country

8.4.4.1. United Kingdom

8.4.4.1.1. Market Trends and Opportunities

8.4.4.1.2. Growth Prospects

8.4.4.2. Germany

8.4.4.2.1. Market Trends and Opportunities

8.4.4.2.2. Growth Prospects

8.4.4.3. France

8.4.4.3.1. Market Trends and Opportunities

8.4.4.3.2. Growth Prospects

8.4.4.4. Italy

8.4.4.4.1. Market Trends and Opportunities

8.4.4.4.2. Growth Prospects

8.4.4.5. Spain

8.4.4.5.1. Market Trends and Opportunities

8.4.4.5.2. Growth Prospects

8.4.4.6. Others

8.4.4.6.1. Market Trends and Opportunities

8.4.4.6.2. Growth Prospects

8.5. Middle East and Africa

8.5.1. By Route of Administration 

8.5.2. By Mode of NDDS

8.5.3. By End User

8.5.4. By Country

8.5.4.1. Saudi Arabia

8.5.4.1.1. Market Trends and Opportunities

8.5.4.1.2. Growth Prospects

8.5.4.2. UAE

8.5.4.2.1. Market Trends and Opportunities

8.5.4.2.2. Growth Prospects

8.5.4.3. Others

8.5.4.3.1. Market Trends and Opportunities

8.5.4.3.2. Growth Prospects

8.6. Asia Pacific

8.6.1. By Route of Administration 

8.6.2. By Mode of NDDS

8.6.3. By End User

8.6.4. By Country

8.6.4.1. Japan

8.6.4.1.1. Market Trends and Opportunities

8.6.4.1.2. Growth Prospects

8.6.4.2. China

8.6.4.2.1. Market Trends and Opportunities

8.6.4.2.2. Growth Prospects

8.6.4.3. India

8.6.4.3.1. Market Trends and Opportunities

8.6.4.3.2. Growth Prospects

8.6.4.4. South Korea

8.6.4.4.1. Market Trends and Opportunities

8.6.4.4.2. Growth Prospects

8.6.4.5. Taiwan

8.6.4.5.1. Market Trends and Opportunities

8.6.4.5.2. Growth Prospects

8.6.4.6. Thailand

8.6.4.6.1. Market Trends and Opportunities

8.6.4.6.2. Growth Prospects

8.6.4.7. Indonesia

8.6.4.7.1. Market Trends and Opportunities

8.6.4.7.2. Growth Prospects

8.6.4.8. Others

8.6.4.8.1. Market Trends and Opportunities

8.6.4.8.2. Growth Prospects

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Competitive Dashboard

10. COMPANY PROFILES

10.1. Abbott Laboratories

10.2. Amgen Inc

10.3. AstraZeneca PLC

10.4. Bayer AG

10.5. Boston Scientific Corporation

10.6. Bristol-Myers Squibb

10.7. Celgene Corporation

10.8. F. Hoffmann-La Roche AG

10.9. GlaxoSmithKline PLC

Abbott Laboratories

Amgen Inc

AstraZeneca PLC

Bayer AG

Boston Scientific Corporation

Bristol-Myers Squibb

Celgene Corporation

F. Hoffmann-La Roche AG

 

GlaxoSmithKline PLC